SYNLOGIC, INC. (SYBX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.96

From 52W high−47.54%

Volume11101.00

Market cap$11.83M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.96

From 52W high

−47.54%

Volume

11101.00

Market cap

$11.83M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.4x

P/E (TTM)

—

RSI (14)

30.5

MomentumView details →

1D Return

−3.99%

YTD Return

−14.28%

SummaryUpdated Jun 1, 2026

Synlogic, Inc. (NASDAQ:SYBX) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts. The company went public in September 2015 and focuses on developing synthetic biotic medicines, which are engineered microorganisms designed to treat metabolic and immunological diseases. Synlogic represents a novel approach in biotechnology, using genetically modified bacteria as therapeutic agents rather than traditional small molecule drugs or biologics.

Ask drillr about SYNLOGIC, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−5.45%

ROA (TTM)

−4.86%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+38.06%

FCF YoY

−19.53%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+95.83%

EBITDA YoY

—

MomentumView details →

1D Return

−3.99%

YTD Return

−14.28%

1Y Return

−44.50%

RSI (14)

30.5

vs 50D SMA

−16.90%

vs 200D SMA

+15.97%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.19x

Quick Ratio

9.19x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.04

EPS Surprise

—

Beats (12Q)

5/12

Next Q EPS Est

−$4.63

Avg Surprise (4Q)

41.97%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−655000.00

Op. CF (TTM)

−3.84M

Next earningsNov 11, 2026 →

Latest newsMore news →

Caldera Therapeutics entered into a definitive merger agreement for an all-stock merger with Synlogic, becoming wholly owned subsidiaries of a new holding company, and the combined company will operate as Caldera Therapeutics, Inc. and list on Nasdaq under ticker CALD.82d ago

Similar companies

Aspire Biopharma Holdings, Inc.ASBP BioVie Inc.BIVI Citius Pharmaceuticals, Inc.CTXR Tevogen Bio Holdings Inc.TVGNW GT Biopharma, Inc.GTBP Passage Bio, Inc.PASG Find similar companies →

Latest newsMore news →